Piper Sandler initiated coverage on Carlsmed with a new price target
$CARL
Medical/Dental Instruments
Health Care
Piper Sandler initiated coverage of Carlsmed with a rating of Overweight and set a new price target of $18.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/18/2025 | $19.00 | Buy | Goldman |
| 8/18/2025 | $18.00 | Overweight | Piper Sandler |
| 8/18/2025 | $18.00 | Buy | Truist |
| 8/18/2025 | $21.00 | Buy | BTIG Research |
| 8/18/2025 | $16.00 | Buy | BofA Securities |
4 - CARLSMED, INC. (0001794546) (Issuer)
4 - CARLSMED, INC. (0001794546) (Issuer)
4 - CARLSMED, INC. (0001794546) (Issuer)
Goldman initiated coverage of Carlsmed with a rating of Buy and set a new price target of $19.00
Piper Sandler initiated coverage of Carlsmed with a rating of Overweight and set a new price target of $18.00
Truist initiated coverage of Carlsmed with a rating of Buy and set a new price target of $18.00
4 - CARLSMED, INC. (0001794546) (Issuer)
4 - CARLSMED, INC. (0001794546) (Issuer)
4 - CARLSMED, INC. (0001794546) (Issuer)
CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 25th Annual Needham Virtual Conference on April 13, 2026 at 11:45 AM ET. A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://event.summitcast.com/view/cCMfZsH5ZqrwSNTwfC9JDv/RczDxtnmshQKpi2ivHQcH3 About Carlsmed, Inc. Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and bey
Fourth quarter revenue of $15.2 million; 61% growth YoY Full year revenue of $50.5 million; 86% growth YoY CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. "We delivered another very strong quarter with 61% revenue growth year-over-year, gross margin expansion to 76.5%, and reduction of our lead times to within six business days. These achievements demonstrate our momentum and the speed at which we are scaling while maintaining our culture o
CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 2026 Canaccord Genuity Musculoskeletal Conference on March 2, 2026 at 11:30 AM CST in New Orleans, LA. A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://event.summitcast.com/view/d69xRqMspwymhwGUDdQoes/JC9qqvWhWggYawxGnDNtmz About Carlsmed, Inc. Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healt
S-8 - CARLSMED, INC. (0001794546) (Filer)
10-K - CARLSMED, INC. (0001794546) (Filer)
8-K - CARLSMED, INC. (0001794546) (Filer)
CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective immediately. Ms. Kamocsay will serve as legal counsel for the Company and oversee compliance and corporate governance. Ms. Kamocsay brings more than two decades of corporate legal experience as in-house counsel across life science and technology sectors at Akoya Biosicences, Rubius Therapeutics, Inc. and Progress Software Corporation. "We are pleased to welcome Jennifer to the Carlsmed
Fourth quarter revenue of $15.2 million; 61% growth YoY Full year revenue of $50.5 million; 86% growth YoY CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. "We delivered another very strong quarter with 61% revenue growth year-over-year, gross margin expansion to 76.5%, and reduction of our lead times to within six business days. These achievements demonstrate our momentum and the speed at which we are scaling while maintaining our culture o
CARLSBAD, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its fourth quarter and full year 2025 financial results after market close on Wednesday, February 25, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the start of the conference call. Event Date: Wednesday, February 25, 2026Time: 1:30 PM Pacific Time Participant Registration: https://register-conf.media-server.com/register/BIb45
Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025. "We delivered another strong quarter with 98% revenue growth year-over-year, expanded gross margins to 76%, increased surgeon users by more than 70% year-over-year, and reduced lead times to within 8 business days. These achievements demonstrate the incredible momentum and